Elizabeth McFarland
Concepts (374)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV-1 | 26 | 2025 | 840 | 2.950 |
Why?
| HIV Infections | 47 | 2025 | 2703 | 2.880 |
Why?
| Respiratory Syncytial Virus Vaccines | 6 | 2022 | 32 | 2.420 |
Why?
| Respiratory Syncytial Virus Infections | 6 | 2022 | 117 | 2.230 |
Why?
| Respiratory Syncytial Virus, Human | 6 | 2022 | 68 | 2.210 |
Why?
| Infectious Disease Transmission, Vertical | 17 | 2025 | 165 | 2.150 |
Why?
| HIV Antibodies | 12 | 2025 | 57 | 2.110 |
Why?
| Anti-Retroviral Agents | 12 | 2023 | 230 | 1.790 |
Why?
| Viral Proteins | 3 | 2020 | 321 | 1.630 |
Why?
| Antibodies, Viral | 8 | 2022 | 593 | 1.170 |
Why?
| Antibodies, Neutralizing | 8 | 2025 | 255 | 1.140 |
Why?
| Antibodies, Monoclonal | 6 | 2025 | 1355 | 0.910 |
Why?
| Anti-HIV Agents | 11 | 2025 | 747 | 0.900 |
Why?
| AIDS Vaccines | 8 | 2018 | 47 | 0.890 |
Why?
| Pregnancy Complications, Infectious | 8 | 2016 | 335 | 0.810 |
Why?
| Gene Deletion | 2 | 2020 | 372 | 0.750 |
Why?
| Breast Feeding | 4 | 2025 | 421 | 0.670 |
Why?
| Atazanavir Sulfate | 2 | 2017 | 41 | 0.660 |
Why?
| HIV Protease Inhibitors | 2 | 2017 | 61 | 0.640 |
Why?
| Ritonavir | 2 | 2017 | 72 | 0.630 |
Why?
| Vaccination | 6 | 2020 | 1336 | 0.600 |
Why?
| Infant, Newborn | 23 | 2025 | 5687 | 0.600 |
Why?
| Vaccines, Attenuated | 6 | 2022 | 123 | 0.600 |
Why?
| HIV Envelope Protein gp120 | 6 | 2017 | 57 | 0.590 |
Why?
| Infant | 31 | 2025 | 8913 | 0.540 |
Why?
| Nelfinavir | 1 | 2016 | 8 | 0.520 |
Why?
| Lopinavir | 1 | 2016 | 30 | 0.510 |
Why?
| Syncope | 1 | 2016 | 50 | 0.510 |
Why?
| Patient Dropouts | 1 | 2016 | 65 | 0.510 |
Why?
| Bradycardia | 1 | 2016 | 55 | 0.510 |
Why?
| Lyme Disease | 1 | 2016 | 50 | 0.500 |
Why?
| Health Resources | 1 | 2016 | 120 | 0.480 |
Why?
| Infant, Newborn, Diseases | 1 | 2016 | 108 | 0.460 |
Why?
| HIV | 5 | 2014 | 226 | 0.430 |
Why?
| Patient Compliance | 2 | 2018 | 562 | 0.420 |
Why?
| Immunogenicity, Vaccine | 4 | 2021 | 26 | 0.400 |
Why?
| Child | 36 | 2023 | 20721 | 0.380 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 2017 | 1046 | 0.370 |
Why?
| T-Lymphocytes, Cytotoxic | 4 | 2005 | 168 | 0.370 |
Why?
| Virus Replication | 4 | 2020 | 444 | 0.370 |
Why?
| Humans | 71 | 2025 | 128524 | 0.360 |
Why?
| Female | 47 | 2025 | 68127 | 0.350 |
Why?
| Lymphocyte Activation | 5 | 2017 | 1098 | 0.320 |
Why?
| Male | 38 | 2025 | 62883 | 0.310 |
Why?
| Viral Load | 9 | 2017 | 450 | 0.290 |
Why?
| HIV Seropositivity | 2 | 2023 | 119 | 0.280 |
Why?
| Adolescent | 26 | 2023 | 20213 | 0.280 |
Why?
| Double-Blind Method | 3 | 2020 | 1860 | 0.270 |
Why?
| RNA, Viral | 8 | 2023 | 614 | 0.270 |
Why?
| Antibodies, Bacterial | 2 | 2018 | 136 | 0.250 |
Why?
| Antiretroviral Therapy, Highly Active | 6 | 2017 | 266 | 0.240 |
Why?
| Dyslipidemias | 2 | 2017 | 177 | 0.240 |
Why?
| Immunoenzyme Techniques | 1 | 2005 | 206 | 0.230 |
Why?
| Immunoglobulin G | 3 | 2022 | 837 | 0.230 |
Why?
| Colonography, Computed Tomographic | 1 | 2024 | 6 | 0.220 |
Why?
| Viremia | 3 | 2011 | 130 | 0.220 |
Why?
| Diverticulum | 1 | 2024 | 11 | 0.220 |
Why?
| Child, Preschool | 21 | 2022 | 10373 | 0.220 |
Why?
| Gene Products, gag | 2 | 1994 | 36 | 0.220 |
Why?
| Mammography | 1 | 2025 | 143 | 0.220 |
Why?
| Young Adult | 12 | 2021 | 12320 | 0.210 |
Why?
| Pregnancy | 11 | 2023 | 6297 | 0.210 |
Why?
| Squalene | 3 | 2017 | 7 | 0.210 |
Why?
| Complementarity Determining Regions | 1 | 2002 | 49 | 0.200 |
Why?
| Drug Resistance, Viral | 2 | 2016 | 111 | 0.190 |
Why?
| CD4 Lymphocyte Count | 4 | 2017 | 265 | 0.190 |
Why?
| Half-Life | 1 | 2021 | 144 | 0.190 |
Why?
| Growth Differentiation Factor 15 | 1 | 2021 | 39 | 0.190 |
Why?
| Mitochondrial Diseases | 1 | 2021 | 89 | 0.180 |
Why?
| Immunization Schedule | 2 | 2018 | 197 | 0.180 |
Why?
| T-Lymphocytes | 2 | 2009 | 1922 | 0.180 |
Why?
| Drug Therapy, Combination | 4 | 2017 | 1009 | 0.180 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 334 | 0.170 |
Why?
| Fibroblast Growth Factors | 1 | 2021 | 171 | 0.170 |
Why?
| RNA, Small Untranslated | 1 | 2020 | 15 | 0.170 |
Why?
| env Gene Products, Human Immunodeficiency Virus | 2 | 2017 | 15 | 0.170 |
Why?
| Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 185 | 0.160 |
Why?
| Cytokines | 2 | 2021 | 1985 | 0.160 |
Why?
| Body Temperature | 1 | 2020 | 215 | 0.160 |
Why?
| Point Mutation | 1 | 2020 | 224 | 0.160 |
Why?
| Immunologic Memory | 2 | 2021 | 339 | 0.150 |
Why?
| Insulin Resistance | 3 | 2019 | 1166 | 0.150 |
Why?
| Haemophilus Vaccines | 2 | 2018 | 28 | 0.150 |
Why?
| Immunocompromised Host | 2 | 2000 | 195 | 0.150 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2011 | 840 | 0.150 |
Why?
| Metabolic Syndrome | 1 | 2021 | 340 | 0.150 |
Why?
| Darunavir | 1 | 2017 | 17 | 0.140 |
Why?
| Interleukin-12 | 1 | 1998 | 120 | 0.140 |
Why?
| Dose-Response Relationship, Drug | 1 | 2021 | 1943 | 0.140 |
Why?
| Therapeutic Equipoise | 1 | 2017 | 2 | 0.140 |
Why?
| Interferon-gamma | 5 | 2012 | 761 | 0.140 |
Why?
| Immunoglobulin A | 2 | 2017 | 192 | 0.140 |
Why?
| Uganda | 1 | 2017 | 72 | 0.140 |
Why?
| Antibody Formation | 1 | 2018 | 287 | 0.140 |
Why?
| Lymphopoiesis | 1 | 2017 | 26 | 0.140 |
Why?
| Mycobacterium Infections, Nontuberculous | 2 | 2012 | 377 | 0.140 |
Why?
| High-Throughput Screening Assays | 1 | 2018 | 136 | 0.140 |
Why?
| Receptors, CCR5 | 1 | 2017 | 58 | 0.140 |
Why?
| CD4-CD8 Ratio | 1 | 2016 | 22 | 0.130 |
Why?
| HIV-Associated Lipodystrophy Syndrome | 1 | 2016 | 12 | 0.130 |
Why?
| Adoption | 1 | 2016 | 33 | 0.130 |
Why?
| Mothers | 3 | 2017 | 728 | 0.130 |
Why?
| Virus Latency | 1 | 2016 | 77 | 0.130 |
Why?
| Adult | 15 | 2023 | 35315 | 0.120 |
Why?
| Chickenpox Vaccine | 1 | 2015 | 71 | 0.120 |
Why?
| Continuity of Patient Care | 1 | 2018 | 278 | 0.120 |
Why?
| Early Diagnosis | 1 | 2016 | 236 | 0.120 |
Why?
| Body Height | 2 | 2017 | 192 | 0.120 |
Why?
| Zimbabwe | 2 | 2025 | 54 | 0.120 |
Why?
| Gene Products, env | 1 | 1994 | 6 | 0.120 |
Why?
| Disease Susceptibility | 1 | 2017 | 334 | 0.120 |
Why?
| Haemophilus influenzae type b | 1 | 2014 | 10 | 0.120 |
Why?
| Bacterial Capsules | 1 | 2014 | 28 | 0.120 |
Why?
| Chickenpox | 1 | 2015 | 78 | 0.120 |
Why?
| Antibody Affinity | 1 | 2014 | 59 | 0.120 |
Why?
| South Africa | 2 | 2025 | 192 | 0.110 |
Why?
| Acquired Immunodeficiency Syndrome | 2 | 2000 | 222 | 0.110 |
Why?
| Cote d'Ivoire | 2 | 2025 | 9 | 0.110 |
Why?
| Parotitis | 1 | 2014 | 6 | 0.110 |
Why?
| Vaccines, Synthetic | 4 | 2005 | 126 | 0.110 |
Why?
| Developing Countries | 1 | 2016 | 283 | 0.110 |
Why?
| Lipids | 1 | 2017 | 624 | 0.110 |
Why?
| Puberty, Delayed | 1 | 2013 | 5 | 0.110 |
Why?
| Cytotoxicity, Immunologic | 3 | 2002 | 218 | 0.110 |
Why?
| Intestines | 1 | 2017 | 345 | 0.110 |
Why?
| Leukocytes, Mononuclear | 4 | 2013 | 538 | 0.110 |
Why?
| Retrospective Studies | 8 | 2023 | 14460 | 0.110 |
Why?
| Vaccines | 1 | 2018 | 393 | 0.110 |
Why?
| RNA-Directed DNA Polymerase | 1 | 1993 | 34 | 0.110 |
Why?
| Patient Selection | 1 | 2017 | 661 | 0.100 |
Why?
| Mycobacterium chelonae | 1 | 1993 | 9 | 0.100 |
Why?
| Breast Neoplasms | 1 | 2025 | 2139 | 0.100 |
Why?
| Mitochondria | 2 | 2021 | 844 | 0.100 |
Why?
| Lamivudine | 3 | 2023 | 61 | 0.100 |
Why?
| Cohort Studies | 7 | 2021 | 5369 | 0.100 |
Why?
| Bone Density | 1 | 2016 | 476 | 0.100 |
Why?
| Cell Movement | 1 | 2017 | 937 | 0.100 |
Why?
| Child Development | 1 | 2017 | 452 | 0.100 |
Why?
| Pediatric Obesity | 1 | 2019 | 572 | 0.100 |
Why?
| Clinical Trials as Topic | 1 | 2017 | 998 | 0.100 |
Why?
| Cardiovascular Diseases | 2 | 2016 | 2018 | 0.100 |
Why?
| STAT1 Transcription Factor | 1 | 2012 | 70 | 0.100 |
Why?
| Prospective Studies | 4 | 2017 | 7043 | 0.100 |
Why?
| Body Weight | 2 | 2017 | 931 | 0.090 |
Why?
| Polysorbates | 3 | 2017 | 38 | 0.090 |
Why?
| Body Fat Distribution | 1 | 2011 | 49 | 0.090 |
Why?
| Mycobacterium avium Complex | 1 | 2012 | 90 | 0.090 |
Why?
| Epitopes | 2 | 2022 | 466 | 0.090 |
Why?
| United States | 9 | 2023 | 13876 | 0.090 |
Why?
| Cost-Benefit Analysis | 2 | 2025 | 581 | 0.090 |
Why?
| Research Design | 1 | 2017 | 1038 | 0.090 |
Why?
| Biomedical Research | 1 | 2017 | 646 | 0.090 |
Why?
| Interleukin-2 | 2 | 2003 | 430 | 0.080 |
Why?
| Exercise | 1 | 2021 | 1937 | 0.080 |
Why?
| Respiratory Tract Infections | 1 | 2014 | 370 | 0.080 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2016 | 551 | 0.080 |
Why?
| Freezing | 1 | 2009 | 86 | 0.080 |
Why?
| Blood | 1 | 2009 | 100 | 0.080 |
Why?
| Algorithms | 1 | 2016 | 1616 | 0.080 |
Why?
| Staff Development | 1 | 2009 | 56 | 0.080 |
Why?
| Age Factors | 4 | 2019 | 3117 | 0.080 |
Why?
| Phenotype | 1 | 2017 | 3050 | 0.070 |
Why?
| Biomarkers | 4 | 2021 | 3881 | 0.070 |
Why?
| T-Lymphocyte Subsets | 2 | 2002 | 410 | 0.070 |
Why?
| Specimen Handling | 1 | 2009 | 165 | 0.070 |
Why?
| Lymphocyte Subsets | 2 | 2009 | 85 | 0.070 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 814 | 0.070 |
Why?
| Faculty | 1 | 2009 | 135 | 0.070 |
Why?
| Withholding Treatment | 1 | 2008 | 70 | 0.070 |
Why?
| Adipose Tissue | 1 | 2011 | 591 | 0.070 |
Why?
| Enterovirus A, Human | 1 | 2007 | 12 | 0.070 |
Why?
| Polymerase Chain Reaction | 4 | 2011 | 1019 | 0.070 |
Why?
| Central Nervous System Viral Diseases | 1 | 2007 | 73 | 0.070 |
Why?
| Flow Cytometry | 3 | 2009 | 1141 | 0.060 |
Why?
| Academic Medical Centers | 1 | 2009 | 473 | 0.060 |
Why?
| DNA, Viral | 2 | 2000 | 348 | 0.060 |
Why?
| False Negative Reactions | 1 | 2025 | 50 | 0.060 |
Why?
| Isoantigens | 1 | 1984 | 12 | 0.060 |
Why?
| Cell Line | 3 | 2012 | 2731 | 0.060 |
Why?
| Medical Audit | 1 | 2025 | 76 | 0.060 |
Why?
| C-Reactive Protein | 2 | 2021 | 396 | 0.060 |
Why?
| Enterovirus Infections | 1 | 2007 | 171 | 0.060 |
Why?
| Colorado | 3 | 2023 | 4392 | 0.060 |
Why?
| Disease Outbreaks | 1 | 2007 | 334 | 0.060 |
Why?
| Immunity, Cellular | 1 | 2006 | 267 | 0.060 |
Why?
| Follow-Up Studies | 3 | 2021 | 4898 | 0.060 |
Why?
| Linear Models | 2 | 2020 | 816 | 0.060 |
Why?
| Confusion | 1 | 2024 | 27 | 0.050 |
Why?
| Comorbidity | 2 | 2021 | 1540 | 0.050 |
Why?
| Sequence Analysis, DNA | 2 | 2007 | 773 | 0.050 |
Why?
| Thymus Gland | 1 | 1984 | 309 | 0.050 |
Why?
| Risk Factors | 4 | 2021 | 9727 | 0.050 |
Why?
| Tablets | 1 | 2023 | 37 | 0.050 |
Why?
| Constriction, Pathologic | 1 | 2024 | 229 | 0.050 |
Why?
| Regression Analysis | 2 | 2021 | 983 | 0.050 |
Why?
| Respiratory Syncytial Viruses | 1 | 2022 | 52 | 0.050 |
Why?
| Genes, T-Cell Receptor beta | 1 | 2002 | 21 | 0.050 |
Why?
| Immunophenotyping | 2 | 1994 | 312 | 0.050 |
Why?
| Zidovudine | 2 | 2015 | 77 | 0.050 |
Why?
| Clone Cells | 1 | 2002 | 254 | 0.050 |
Why?
| Dose-Response Relationship, Immunologic | 1 | 2001 | 81 | 0.050 |
Why?
| Cough | 1 | 2022 | 116 | 0.050 |
Why?
| Emtricitabine | 1 | 2023 | 168 | 0.050 |
Why?
| Vaccines, Subunit | 1 | 2001 | 47 | 0.050 |
Why?
| Tenofovir | 1 | 2023 | 231 | 0.050 |
Why?
| Pyridones | 1 | 2023 | 159 | 0.050 |
Why?
| Lung | 1 | 2014 | 3741 | 0.050 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2021 | 49 | 0.050 |
Why?
| Public Health Surveillance | 1 | 2021 | 67 | 0.040 |
Why?
| Ganciclovir | 1 | 2000 | 51 | 0.040 |
Why?
| Computer Simulation | 1 | 2005 | 939 | 0.040 |
Why?
| Adjuvants, Immunologic | 2 | 2017 | 221 | 0.040 |
Why?
| Africa | 1 | 2020 | 98 | 0.040 |
Why?
| Injections, Subcutaneous | 1 | 2020 | 145 | 0.040 |
Why?
| Cross-Sectional Studies | 3 | 2021 | 5040 | 0.040 |
Why?
| Sex Factors | 2 | 2019 | 1949 | 0.040 |
Why?
| Diagnostic Tests, Routine | 1 | 2021 | 103 | 0.040 |
Why?
| Symptom Assessment | 1 | 2021 | 125 | 0.040 |
Why?
| HIV Seronegativity | 1 | 2019 | 25 | 0.040 |
Why?
| HLA-D Antigens | 1 | 1999 | 34 | 0.040 |
Why?
| Risk | 1 | 2021 | 852 | 0.040 |
Why?
| Case-Control Studies | 2 | 2019 | 3326 | 0.040 |
Why?
| Prevalence | 2 | 2016 | 2549 | 0.040 |
Why?
| Cytomegalovirus Infections | 1 | 2000 | 187 | 0.040 |
Why?
| Lymphocyte Culture Test, Mixed | 1 | 1998 | 48 | 0.040 |
Why?
| Hospitals | 1 | 2023 | 631 | 0.040 |
Why?
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2018 | 25 | 0.040 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 1998 | 42 | 0.040 |
Why?
| Vaccines, Combined | 1 | 2018 | 48 | 0.040 |
Why?
| Poliovirus Vaccine, Inactivated | 1 | 2018 | 22 | 0.040 |
Why?
| Cholesterol, HDL | 1 | 2019 | 203 | 0.040 |
Why?
| Amino Acid Sequence | 1 | 2002 | 2041 | 0.040 |
Why?
| Longitudinal Studies | 2 | 2017 | 2697 | 0.040 |
Why?
| Mutation | 3 | 2018 | 3692 | 0.040 |
Why?
| Odds Ratio | 1 | 2021 | 1022 | 0.040 |
Why?
| Hepatitis B Vaccines | 1 | 2018 | 48 | 0.040 |
Why?
| Drug Resistance, Microbial | 2 | 2000 | 63 | 0.040 |
Why?
| Molecular Sequence Data | 1 | 2002 | 2818 | 0.040 |
Why?
| Case Management | 1 | 2018 | 63 | 0.040 |
Why?
| Nutrition Surveys | 1 | 2019 | 262 | 0.040 |
Why?
| Antigens, Viral | 1 | 1998 | 174 | 0.040 |
Why?
| Cholesterol | 1 | 2019 | 406 | 0.030 |
Why?
| Cholesterol, LDL | 1 | 2019 | 361 | 0.030 |
Why?
| Reproducibility of Results | 1 | 2005 | 3023 | 0.030 |
Why?
| Epitopes, T-Lymphocyte | 1 | 1998 | 185 | 0.030 |
Why?
| Immune Tolerance | 1 | 1999 | 345 | 0.030 |
Why?
| Treatment Adherence and Compliance | 1 | 2017 | 22 | 0.030 |
Why?
| Disease Management | 1 | 2021 | 588 | 0.030 |
Why?
| Triglycerides | 1 | 2019 | 524 | 0.030 |
Why?
| Lymphocyte Count | 2 | 2009 | 150 | 0.030 |
Why?
| Cell Division | 1 | 1998 | 779 | 0.030 |
Why?
| Uncertainty | 1 | 2017 | 114 | 0.030 |
Why?
| Treatment Failure | 1 | 2017 | 342 | 0.030 |
Why?
| Multicenter Studies as Topic | 1 | 2017 | 285 | 0.030 |
Why?
| Nevirapine | 1 | 2015 | 16 | 0.030 |
Why?
| Time-to-Treatment | 1 | 2017 | 180 | 0.030 |
Why?
| Seroepidemiologic Studies | 1 | 2015 | 156 | 0.030 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2021 | 1358 | 0.030 |
Why?
| Maternal Exposure | 1 | 2017 | 173 | 0.030 |
Why?
| Malnutrition | 1 | 2016 | 78 | 0.030 |
Why?
| Patient Outcome Assessment | 1 | 2016 | 127 | 0.030 |
Why?
| Genes, pol | 1 | 1994 | 7 | 0.030 |
Why?
| Antiviral Agents | 1 | 2000 | 704 | 0.030 |
Why?
| Treatment Outcome | 2 | 2021 | 10163 | 0.030 |
Why?
| Coinfection | 1 | 2016 | 131 | 0.030 |
Why?
| Neutropenia | 1 | 2015 | 136 | 0.030 |
Why?
| Vaccines, Conjugate | 1 | 2014 | 63 | 0.030 |
Why?
| Counseling | 1 | 2018 | 386 | 0.030 |
Why?
| Sexual and Gender Minorities | 1 | 2018 | 186 | 0.030 |
Why?
| Global Health | 1 | 2017 | 326 | 0.030 |
Why?
| Cells, Cultured | 2 | 2008 | 4008 | 0.030 |
Why?
| Anemia | 1 | 2015 | 156 | 0.030 |
Why?
| Maternal-Fetal Exchange | 1 | 2014 | 161 | 0.030 |
Why?
| Electron Transport Complex IV | 1 | 2013 | 57 | 0.030 |
Why?
| Electron Transport Complex I | 1 | 2013 | 38 | 0.030 |
Why?
| Thrombocytopenia | 1 | 2015 | 182 | 0.030 |
Why?
| Tuberculosis, Cutaneous | 1 | 1993 | 3 | 0.030 |
Why?
| HIV Reverse Transcriptase | 1 | 1993 | 30 | 0.030 |
Why?
| Radiography, Thoracic | 1 | 2014 | 163 | 0.030 |
Why?
| CD8 Antigens | 1 | 1993 | 75 | 0.030 |
Why?
| Severity of Illness Index | 1 | 2021 | 2736 | 0.030 |
Why?
| CD3 Complex | 1 | 1993 | 101 | 0.030 |
Why?
| Drug Administration Schedule | 2 | 2008 | 757 | 0.030 |
Why?
| Lymphocytes | 1 | 1994 | 366 | 0.030 |
Why?
| Oxidative Phosphorylation | 1 | 2013 | 184 | 0.020 |
Why?
| Medication Adherence | 1 | 2017 | 573 | 0.020 |
Why?
| Blood Pressure | 1 | 2019 | 1733 | 0.020 |
Why?
| DNA, Mitochondrial | 1 | 2013 | 192 | 0.020 |
Why?
| Blood Transfusion | 1 | 1994 | 293 | 0.020 |
Why?
| P-Selectin | 1 | 2011 | 26 | 0.020 |
Why?
| Antigens, CD | 1 | 1994 | 479 | 0.020 |
Why?
| E-Selectin | 1 | 2011 | 53 | 0.020 |
Why?
| Heteroduplex Analysis | 1 | 2011 | 1 | 0.020 |
Why?
| Tuberculosis, Pulmonary | 1 | 1993 | 137 | 0.020 |
Why?
| Chemokine CCL2 | 1 | 2011 | 117 | 0.020 |
Why?
| Hospitalization | 1 | 2021 | 2071 | 0.020 |
Why?
| Cell Proliferation | 2 | 2009 | 2335 | 0.020 |
Why?
| Hyperlipidemias | 1 | 2011 | 126 | 0.020 |
Why?
| Fibrinogen | 1 | 2011 | 158 | 0.020 |
Why?
| Protein Multimerization | 1 | 2012 | 178 | 0.020 |
Why?
| Cross Infection | 1 | 1993 | 196 | 0.020 |
Why?
| Absorptiometry, Photon | 1 | 2011 | 250 | 0.020 |
Why?
| Interferon-alpha | 1 | 2012 | 192 | 0.020 |
Why?
| Cell Adhesion Molecules | 1 | 2011 | 172 | 0.020 |
Why?
| Healthcare Disparities | 1 | 2017 | 576 | 0.020 |
Why?
| Infant, Premature | 1 | 1994 | 536 | 0.020 |
Why?
| Nontuberculous Mycobacteria | 1 | 1993 | 228 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2014 | 1416 | 0.020 |
Why?
| Pokeweed Mitogens | 1 | 2009 | 7 | 0.020 |
Why?
| L-Selectin | 1 | 2009 | 24 | 0.020 |
Why?
| Human Experimentation | 1 | 2009 | 12 | 0.020 |
Why?
| Tetanus | 1 | 2009 | 25 | 0.020 |
Why?
| Candida | 1 | 2009 | 35 | 0.020 |
Why?
| Leukocyte Common Antigens | 1 | 2009 | 81 | 0.020 |
Why?
| Obesity | 1 | 2021 | 2860 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2011 | 1494 | 0.020 |
Why?
| Meningitis, Aseptic | 1 | 2007 | 14 | 0.020 |
Why?
| Virus Cultivation | 1 | 2007 | 28 | 0.020 |
Why?
| Interleukin-6 | 1 | 2011 | 716 | 0.020 |
Why?
| Phosphorylation | 1 | 2012 | 1681 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2009 | 335 | 0.020 |
Why?
| Pregnancy Outcome | 1 | 2010 | 383 | 0.020 |
Why?
| Cerebrospinal Fluid | 1 | 2007 | 89 | 0.020 |
Why?
| Multiple Organ Failure | 1 | 2007 | 121 | 0.020 |
Why?
| Paralysis | 1 | 2007 | 72 | 0.020 |
Why?
| B-Lymphocytes | 1 | 2012 | 820 | 0.020 |
Why?
| Kinetics | 1 | 2010 | 1616 | 0.020 |
Why?
| Respiratory System | 1 | 2007 | 153 | 0.020 |
Why?
| Genotype | 1 | 2011 | 1831 | 0.020 |
Why?
| Immunoglobulin A, Secretory | 1 | 2005 | 9 | 0.020 |
Why?
| Cell Survival | 1 | 2009 | 1077 | 0.020 |
Why?
| Phosphates | 1 | 1987 | 167 | 0.020 |
Why?
| Muscles | 1 | 1987 | 323 | 0.020 |
Why?
| Encephalitis | 1 | 2007 | 132 | 0.020 |
Why?
| Gastrointestinal Tract | 1 | 2007 | 182 | 0.020 |
Why?
| Mucous Membrane | 1 | 2005 | 120 | 0.010 |
Why?
| Chemistry, Physical | 1 | 1984 | 37 | 0.010 |
Why?
| Antigen-Antibody Reactions | 1 | 1984 | 51 | 0.010 |
Why?
| Chemical Phenomena | 1 | 1984 | 80 | 0.010 |
Why?
| DNA-Binding Proteins | 1 | 2012 | 1415 | 0.010 |
Why?
| Myasthenia Gravis | 1 | 1984 | 22 | 0.010 |
Why?
| Immunologic Deficiency Syndromes | 1 | 1984 | 62 | 0.010 |
Why?
| Saliva | 1 | 2005 | 205 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 2521 | 0.010 |
Why?
| Tissue Distribution | 1 | 1984 | 290 | 0.010 |
Why?
| Aging | 2 | 2003 | 1770 | 0.010 |
Why?
| Blood Glucose | 1 | 2013 | 2092 | 0.010 |
Why?
| Epithelium | 1 | 1984 | 306 | 0.010 |
Why?
| Middle Aged | 2 | 2020 | 30893 | 0.010 |
Why?
| Body Mass Index | 1 | 2011 | 2262 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 1993 | 1667 | 0.010 |
Why?
| Infusions, Intravenous | 1 | 2003 | 384 | 0.010 |
Why?
| Reference Values | 1 | 2003 | 780 | 0.010 |
Why?
| Mice, Inbred BALB C | 1 | 1984 | 1229 | 0.010 |
Why?
| Suspensions | 1 | 2000 | 30 | 0.010 |
Why?
| Capsules | 1 | 2000 | 37 | 0.010 |
Why?
| Urban Population | 1 | 2003 | 438 | 0.010 |
Why?
| Drug Tolerance | 1 | 2000 | 82 | 0.010 |
Why?
| Cytomegalovirus | 1 | 2000 | 153 | 0.010 |
Why?
| Signal Transduction | 1 | 2012 | 4829 | 0.010 |
Why?
| Administration, Oral | 1 | 2000 | 757 | 0.010 |
Why?
| Epithelial Cells | 1 | 1984 | 1036 | 0.010 |
Why?
| Immunization | 1 | 2000 | 411 | 0.010 |
Why?
| Time Factors | 1 | 2008 | 6503 | 0.010 |
Why?
| Macrophages | 1 | 1984 | 1463 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2000 | 1284 | 0.010 |
Why?
| Mice | 1 | 1984 | 16579 | 0.000 |
Why?
| Tail | 1 | 1987 | 29 | 0.000 |
Why?
| Phosphocreatine | 1 | 1987 | 40 | 0.000 |
Why?
| Salamandridae | 1 | 1987 | 26 | 0.000 |
Why?
| Animals | 2 | 1987 | 34501 | 0.000 |
Why?
| Aged | 1 | 1984 | 21971 | 0.000 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 1987 | 508 | 0.000 |
Why?
| Adenosine Triphosphate | 1 | 1987 | 470 | 0.000 |
Why?
|
|
McFarland's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|